Last updated: July 28, 2026
Vicoprofen (hydrocodone bitartrate and ibuprofen): market dynamics, pricing, and financial trajectory
Vicoprofen is a fixed-dose combination opioid analgesic (hydrocodone bitartrate/ibuprofen) marketed by Toray Pharmaceuticals America, Inc. under NDA 020784. The product’s market dynamics are shaped by ongoing opioid risk controls, competitive pressure from generic hydrocodone/ibuprofen alternatives and other analgesics, and continued reimbursement scrutiny. Financial trajectory for Vicoprofen depends on (i) formulary inclusion in commercial plans and PBMs, (ii) opioid utilization controls and prior authorization dynamics, (iii) generic erosion risk in fixed-dose combination space, and (iv) state-level opioid enforcement that disproportionately affects high-volume opioid brands.
What is Vicoprofen’s current market position and sales trend?
Vicoprofen sits in the opioid analgesic class as a branded fixed-dose combination of hydrocodone (opioid) and ibuprofen (NSAID). Market position is determined by how plans treat combination opioid/NSAID products versus immediate-release opioid monotherapy and versus non-opioid analgesics.
How do opioid controls affect Vicoprofen demand?
Key demand headwinds for opioid analgesic brands generally include:
- Increased plan utilization management for hydrocodone-containing products (quantity limits, opioid step therapy, prior authorization).
- Prescriber behavior shifts toward non-opioid regimens and shorter durations.
- Higher scrutiny on opioid prescribing in states with aggressive enforcement and Medicaid pharmacy controls.
- Patient access friction from insurer edits (early refill denials, day-supply limits).
These factors typically reduce growth for branded opioid products and compress share over time, especially when multiple generic equivalents or therapeutically substitutable options exist.
What drives formulary wins and losses for Vicoprofen?
Formulary outcomes for opioid combinations typically pivot on:
- PBM tiering and net price dynamics.
- Prior authorization requirements for hydrocodone products.
- Plan-specific restrictions on combination opioid/NSAID agents.
- Patient co-pay positioning relative to therapeutically equivalent generics and alternative opioid products.
What is the competitive landscape for hydrocodone/ibuprofen fixed-dose combinations?
Vicoprofen competes against:
- Generic hydrocodone/ibuprofen fixed-dose combinations (main competitive pressure when present in a given market).
- Other immediate-release opioid combinations and opioid/acetaminophen products.
- Non-opioid analgesics (including NSAID regimens and adjuvant-based strategies).
Over time, fixed-dose combination brands face share pressure from generic penetration and from payer policies that favor the lowest net-cost products.
What patents protect Vicoprofen and how does that influence pricing power?
Vicoprofen’s commercial durability depends on whether any enforceable patent term remains that prevents generic substitution and whether the product is protected only by expiring compositions or also by method-of-use or formulation patents.
What is the Orange Book status of Vicoprofen?
Vicoprofen is an NDA product and, as such, is listed in the FDA Orange Book with patent and exclusivity information. The extent of remaining listed patents determines whether generics can enter via Paragraph IV certifications (if a generic seeks approval before patent expiration) or via non-Paragraph IV routes after expiry.
How does patent protection translate to financial trajectory?
For branded opioid analgesics, patent protection influences:
- The ability to maintain higher list prices and preserve net pricing.
- The pace of market share erosion from generic entry.
- Litigation-driven settlement outcomes that can delay generic launches and sustain volume for longer.
Where patent estates are thin or core protection is expiring, brands typically show a step-down in sales around generic entry windows due to aggressive payer substitution to lower net-cost products.
When does Vicoprofen lose exclusivity and what are the generic entry risks?
Generic entry risk is a function of:
- Remaining patent expiration dates listed in the Orange Book.
- Any unexpired exclusivity (if applicable).
- The likelihood of Paragraph IV challenges and settlement agreements.
What generic entry risks exist for Vicoprofen?
Generic entry risks for Vicoprofen broadly fall into three pathways:
-
Post-expiration generic launch
- If key patents expire, generics can launch without Paragraph IV litigation.
-
Paragraph IV litigation
- If patents are still in force, a generic may file a Paragraph IV certification, triggering litigation and potential 30-month stay (subject to statutory triggers).
-
Settlement-driven “carve-outs”
- Parties may settle to delay launch dates or limit claims, depending on infringement positions.
For fixed-dose combination opioid products, even partial erosion from early entrants can pressure the brand’s net price through competitive PBM contracting.
What Paragraph IV and patent litigation affects Vicoprofen?
Patent litigation affects the sales curve by changing launch timing and by altering PBM contracting and wholesaler demand forecasts. For opioid analgesics, litigation outcomes also influence payer confidence in continuity of supply and contracting stability.
How do litigation settlements affect Vicoprofen revenue timing?
Settlement patterns often produce:
- A delayed generic launch date compared with a strict statutory timeline.
- A predictable competitive entry window that allows the brand to maintain inventory and negotiate rebate structures until near-term threat dates.
- Post-settlement generic launch acceleration if multiple filers enter in close succession.
A sustained litigation “overhang” can keep incremental demand for the brand higher than would be implied by generic proximity, while a clean path to entry typically compresses sales rapidly post-launch.
How does Vicoprofen compare with hydrocodone/ibuprofen generics on cost and formulary uptake?
The brand’s financial trajectory depends heavily on the “gap” between net costs for the brand versus generic fixed-dose combinations and the payer’s willingness to cover the branded product.
What pricing dynamics typically occur when generics enter?
When generics launch, branded opioid combinations often face:
- Rapid substitution by retail channels and PBM formularies.
- Rebate pressure and net price reductions to keep share.
- Co-pay assistance changes that are usually less effective once payer coverage edits tighten.
- Deeper tiering to non-preferred status for remaining brand share.
What is the likely impact on patient volume and prescriber behavior?
As with other branded opioid products, generic penetration can:
- Lower physician willingness to prescribe a brand when an equivalent generic is preferred by payers.
- Increase switch rates after initial dispensing due to copay and coverage constraints.
- Shift volume into smaller patient cohorts that have specific historical prescriber patterns or access exceptions.
What is Vicoprofen’s FDA regulatory status and how does it affect competition?
Vicoprofen’s FDA regulatory status affects competitor entry through:
- Approved indications and any label constraints.
- Whether the product is eligible for generic substitution after patent expiry.
- Whether changes in labeling alter clinical usage and payer coverage.
What FDA pathway supports generic substitution for Vicoprofen?
Generic hydrocodone/ibuprofen products typically rely on the Abbreviated New Drug Application framework after meeting bioequivalence and patent certification requirements.
If patents remain, generic entry requires Paragraph IV certification and litigation risk management. Once patents expire, generics can submit and launch on a shorter timeline, constrained primarily by manufacturing readiness and market access contracting.
Are there any label or REMS dynamics that constrain demand?
Vicoprofen is subject to the broader regulatory regime applicable to opioid analgesics. Any changes to opioid prescribing controls, REMS-related obligations (if applicable), or FDA safety communications can change payer and prescriber behavior, impacting brand volume even without a direct patent barrier.
Which companies sell Vicoprofen and what is the distribution model?
Vicoprofen is marketed in the US by Toray Pharmaceuticals America, Inc. Distribution is typically through wholesalers to retail pharmacies, with PBM and plan contracting that determines preferred access. Brand sales are shaped by:
- Contracting terms with major PBMs.
- Inclusion on commercial and Medicaid formularies.
- Rebate and patient access programs.
How strong is Vicoprofen’s patent estate compared with other opioid fixed-dose combinations?
For fixed-dose combination opioid analgesics, comparative strength depends on:
- The breadth of composition and method-of-use coverage.
- Whether key patents relate to formulation specifics (e.g., release characteristics) or simply to the active combination.
- The remaining legal life at the time generics could enter.
A stronger estate typically correlates with:
- Lower generic encroachment risk and later substitution.
- Greater ability to maintain share through net price and contracting stability.
A weaker estate usually correlates with:
- Earlier erosion and more volatile sales due to generic launch clustering.
What commercial indicators should be used to track Vicoprofen’s financial trajectory?
For a branded opioid combination, the most actionable indicators are:
- Prescription trends (volume prescriptions and new starts)
- Wholesale acquisition cost and net price changes around generic entry windows
- PBM formulary status changes (preferred vs non-preferred tiers)
- Rebate rate shifts (usually visible indirectly through net sales movements)
- Inventory position shifts around litigation or launch events
Financial trajectory for Vicoprofen typically tracks the timing of:
- Formulary access changes
- Generic launch calendar events
- Rebate renegotiations that follow competitive entry
Key Takeaways
- Vicoprofen’s market dynamics are dominated by payer utilization management and competitive substitution pressure in hydrocodone/ibuprofen fixed-dose combination space.
- Financial trajectory is highly sensitive to Orange Book-listed patent status and any Paragraph IV litigation outcomes that delay or accelerate generic entry.
- Opioid controls and formulary restriction trends generally erode growth prospects for branded opioid analgesics over time, even where supply continuity remains stable.
- Monitoring should focus on prescription trends, net pricing, PBM tiering, and generic entry timing rather than only list price movements.
FAQs
1) Does Vicoprofen face substitution from hydrocodone/ibuprofen generics immediately upon patent expiry?
Yes, when key Orange Book patents expire, generic fixed-dose combinations can typically enter without Paragraph IV litigation, driving rapid payer substitution.
2) How do PBM prior authorization rules usually affect Vicoprofen versus preferred opioid alternatives?
They can reduce script throughput by adding administrative barriers and by shifting prescribers toward preferred agents that clear utilization management more easily.
3) What is the typical sales impact when an opioid combination brand loses preferred formulary status?
Sales often decline quickly due to channel and prescriber switching, followed by smaller cohort stabilization if any access exceptions persist.
4) Are formulation patents common leverage points for opioid combination brands like Vicoprofen?
They can be, but commercial durability depends on whether enforceable patents cover specific formulation or manufacturing aspects beyond the basic fixed-dose combination.
5) How should investors think about litigation overhang risk for Vicoprofen?
Litigation can delay generic entry and stabilize contracting for periods, but sales remain exposed to step-down effects when settlement or expiry enables launch.
References
- FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA: Vicoprofen (hydrocodone bitartrate and ibuprofen). https://www.accessdata.fda.gov/scripts/cder/daf/
